The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Long‐chain n‐3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease
Open accessAbstract
Evidence from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long‐chain n‐3 polyunsaturated fatty acids (LC n‐3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention may also protect from non‐fatal CHD events. The exact mechanisms through which LC n‐3 PUFA has an effect on CHD are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation of platelet aggregation and decreased synthesis of pro‐inflammatory agents. The mechanistic relation between LC n‐3 PUFA and inflammation has attracted great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation pathways) and induce inflammatory resolution. However, the effects of LC n‐3 PUFA on established biomarkers of inflammation and endothelial activation in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of LC n‐3 PUFA on localized inflammatory processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, reduction in atherosclerosis in animal models or humans by administration of OM3FAs has not been convincingly demonstrated [8, 11].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,618
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Cited by
Sorted by citations
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
Bioavailability of bioactive food compounds: a challenging journey to bioefficacy.
Rein, M. J., Renouf, M., Cruz-Hernandez, C., Actis-Goretta, L., Thakkar, S. K., & Pinto, M. I. D. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04425.x · Cited by 763
Foods, Nutrients, and Dietary Patterns: Interconnections and Implications for Dietary Guidelines
Tapsell, L. C., Neale, E. P., Satija, A., & Hu, F. B. (2016) · Advances in Nutrition · doi:10.3945/an.115.011718 · Cited by 744
“Although long-chain n–3 PUFAs may modulate CVD risk through the reduction of plasma TGs and platelet aggregation, and via anti-inflammatory effects (48), preliminary evidence comparing consumption of fish with long-chain n–3 PUFA supplements suggests that consumption of the whole food may deliver additional benefits n…”
BackgroundLayé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“3) (De Roos et al., 2009; Arita, 2012).”
(n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?
Mozaffarian, D., & Wu, J. H. Y. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.149633 · Cited by 368
“, PG-E2, leukotriene-B4, thromboxaneB2) (57) as well as circulating concentrations of epoxyeicosatrienoic acids (58).”
Background
Metadata
- Authors
- de Roos, B., Mavrommatis, Y., & Brouwer, I. A.
- Affiliations
- University of Aberdeen (GB)
- Vrije Universiteit Amsterdam (NL)
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-08-28
- Volume
- 158
- Issue
- 2
- Pages
- 413-428
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2757681
- OpenAlex
- W2148516429
- Cited by
- 151
- References
- 209
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 4 · 2019: 12 · 2018: 11 · 2017: 5 · 2016: 12 · 2015: 10 · 2014: 17 · 2013: 10 · 2012: 18
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Scottish Government
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Physical Sciences › Chemistry › Organic Chemistry › Edible Oils Quality and Analysis
- Keywords
- n-3 long-chain polyunsaturated fatty acids, omega-3 fatty acids, coronary artery disease, inflammation, inflammation resolution, endothelial activation, eicosanoid metabolism, triglycerides, cardiac arrhythmias, platelet aggregation, biomarkers of inflammation, cardiovascular risk
- MeSH terms
- Animals, Clinical Trials as Topic, Coronary Disease, Dose-Response Relationship, Drug, Humans, Inflammation, Biomarkers, Fatty Acids, Omega-3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
